Lung Cancer Trials Ask AI to find trials
CompletedPhase 1 / Phase 2NCT02574078
Official study title

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Study summary

The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNivolumab and Bevacizumab

Plus 9 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 6, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?133 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: Nivolumab; Drug: Bevacizumab; Drug: Pemetrexed; Other: Best Supportive Care; Drug: nab-Paclitaxel; Drug: Paclitaxel; Drug: Docetaxel; Drug: Gemcitabine; Drug: Erlotinib; Drug: Crizotinib; Drug: Carboplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→Targeted therapy→Chemotherapy→Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
  • Histologically confirmed locally advanced or stage IV NSCLC
  • Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2
  • Tumor tissue sections must be available for biomarker evaluation
Reasons someone may not be able to joinExclusion criteria
  • Untreated or active/progressing Central Nervous system (CNS) metastases
  • Active, known or suspected autoimmune disease
  • Known history of testing positive for HIV or AIDS
  • Active or chronic infection of hepatitis B virus or hepatitis C

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Alabama OncologyBirmingham, Alabama
  • Southern Cancer Center PcMobile, Alabama
  • Arizona Oncology Assoc, Pc-HalGlendale, Arizona
  • Northern Arizona Hematology & Oncology AssociatesSedona, Arizona
  • Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) HopeTucson, Arizona
  • Arizona Clinical Research Center, Inc.Tucson, Arizona
  • Comprehensive Blood And Cancer CenterBakersfield, California
  • St. Joseph Heritage Medical GroupFullerton, California
  • Scripps Cancer CenterLa Jolla, California
  • UCLA Hematology/Oncology ClinicLos Angeles, California
  • Coastal Integrative Cancer CareSan Luis Obispo, California
  • Central Coast Med OncologySanta Maria, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 6, 2021. Always confirm current availability with the study team.

View original record ↗